Drug retail market releases chain drugstores or becomes a strong competitor

[market analysis of China Pharmaceutical network] with the promotion of medical reform policy and the outflow of prescription drugs, the retail market capacity of drugs will be extremely broad in the future On the one hand, the outflow of prescription drugs has released huge market space Many pharmaceutical enterprises actively set up retail teams based on their own drug advantages to carry out publicity and promotion, and expand sales channels and layout retail On the other hand, as the direct beneficiary of medicine separation, retail pharmacies are also preparing to undertake the outflow project of prescription drugs (pictures of drug retail market releasing chain drugstores or becoming a strong competitor: Baidu pictures) recently, the 2017 China drug retail industry information conference (SIPC) was held in Boao, Hainan As the annual grand meeting of China's pharmaceutical retail industry, SIPC has entered its 10th year The theme of this year's conference is "building a blueprint - focusing on the market awakening of demand" Under this theme, thousands of enterprises and industry elites gather to discuss the policy, economy, market and other industry hot information of China's pharmaceutical retail industry Recently, Zhongkang CMH released the forecast report on the scale of six drug terminal markets in 2016 In terms of terminals, the scale of drug sales in urban level hospitals reached 800 billion, accounting for 55% of the total scale of the terminal market, followed by county level hospitals, accounting for about 18% It can be seen that the grade hospital is still the terminal of large amount of drugs at present The drugstore terminal keeps a steady upward trend every year, and maintains the growth rate in each terminal [comment] the country started the new medical reform in 2009, and now it has entered the eighth year From the early stage of "strengthening the grassroots, increasing investment" to maintain the high growth trend of the pharmaceutical industry, it has entered the stage of "cost control, efficiency improvement" and return to the rational stage A number of policy documents have been issued, which clearly put forward that hospitals are forbidden to restrict the outflow of prescriptions Patients can choose to purchase drugs in outpatient pharmacies or retail pharmacies based on prescriptions, cancel drug mark ups, eliminate "supporting doctors with drugs", and promote the separation of medicine in various forms This means that the main market for drug allocation will be transferred from hospitals to retail pharmacies With the promotion of medical reform policy and the outflow of prescription drugs, the capacity of drug retail market will be very broad in the future On the one hand, the outflow of prescription drugs has released huge market space Many pharmaceutical enterprises actively set up retail teams based on their own drug advantages to carry out publicity and promotion, expand sales channels and layout retail, such as AstraZeneca, MSD and Sanofi On the other hand, retail pharmacies, as the direct beneficiaries of medicine separation, are also preparing to undertake the outflow project of prescription drugs, including agency resources, training of professional pharmacists and refining professional services Among them, chain drugstores, with their unified, standardized and standardized operation and management, give full play to their cost advantages, logistics management advantages, network advantages and information advantages of drug chain operation, so they become powerful competitors in the future broad drug retail market We are optimistic that with the deepening of medical reform and the concept of great health put forward, with the further release of the retail market of drugs separated from prescription drugs, the structural adjustment and upgrading of the drug retail industry will be promoted, and the drug retail drugstores will be better, among which the chain drugstores are expected to benefit greatly Original title: investment prospect report of pharmaceutical and biological industry: the retail market capacity of drugs will be extremely broad in the future